Clinical trial
Nitrocamptothecin Compared With Gemcitabine in Treating Patients With…
NCT00005869 · Astex Pharmaceuticals, Inc., Industry · Unknown status
Key facts
| NCT number | NCT00005869 |
|---|---|
| Title | Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer |
| Official title | Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Gemcitabine HCl in Chemonaive Pancreatic Cancer Patients |
| Lead sponsor | Astex Pharmaceuticals, Inc., Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, rubitecan |
| Start date | Nov 1, 1998 |
| First posted | Feb 25, 2004 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: